Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 7/20 | 0.41 |
| ▸ | F10 | P00742 | 7/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20546560 | 0.85 | F10 (0.42) | SLC6A3KMT2ASMN1; SMN2F2F10 | |
| SCHEMBL3580558 | 0.83 | KYNU (0.47) | SLC6A3KMT2ASMN1; SMN2F2F10 | |
| SCHEMBL18516122 | 0.83 | AOC3 (0.43) | KMT2ASMN1; SMN2F2F10PRSS1 | |
| SCHEMBL6495546 | 0.83 | CPN1 (0.45) | KMT2ASMN1; SMN2F2F10PRSS1 | |
| SCHEMBL5720896 | 0.83 | KMT2A (0.38) | SLC6A3KMT2ASMN1; SMN2F2F10 | |
| SCHEMBL24036585 | 0.82 | PNP (0.47) | KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21459309 | 0.82 | KCNA5 (0.49) | KMT2ASMN1; SMN2F2F10PRSS1 | |
| SCHEMBL6185468 | 0.82 | L3MBTL1 (0.58) | KMT2ASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL8296972 | 0.82 | KCNA5 (0.49) | KMT2ASMN1; SMN2F2F10PRSS1 | |
| SCHEMBL7422382 | 0.82 | HDAC4 (0.46) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230095637-A1 | Heterodimers of Glutamic Acid | CITIZENS BANK, N.A. | 2023-03-30 | — | — | US | disclosed |
| EP-4023624-A1 | HETERODIMERS OF GLUTAMIC ACID | Molecular Insight Pharmaceuticals, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3699162-B1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARM INC (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3699162-B1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARM INC (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20210246103-A1 | HETERODIMERS OF GLUTAMIC ACID | CITIZENS BANK, N.A. | 2021-08-12 | — | — | US | disclosed |
| US-20210246103-A1 | HETERODIMERS OF GLUTAMIC ACID | CITIZENS BANK, N.A. | 2021-08-12 | — | — | US | disclosed |
| US-20210070695-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20210070696-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20210070696-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20210070695-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20120269726-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | disclosed |
| US-20120269726-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | disclosed |
| US-20120208988-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208988-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2097111-A2 | HETERODIMERS OF GLUTAMIC ACID | Molecular Insight Pharmaceuticals, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008058192-A2 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008058192-A2 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070695-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | SLC6A3 438/4885KMT2A 2413/4885SMN1; SMN2 3022/4885 |
| US-20120269726-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | SLC6A3 449/4885KMT2A 2428/4885SMN1; SMN2 3020/4885 |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | SLC6A3 438/4885KMT2A 2413/4885SMN1; SMN2 3022/4885 |
| US-20210070696-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | SLC6A3 440/4885KMT2A 2402/4885SMN1; SMN2 2993/4885 |
| US-20120208988-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | SLC6A3 438/4885KMT2A 2413/4885SMN1; SMN2 3022/4885 |
| US-20230095637-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | SLC6A3 429/4885KMT2A 2377/4885SMN1; SMN2 3017/4885 |
| US-20210246103-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | SLC6A3 438/4885KMT2A 2413/4885SMN1; SMN2 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.